Matches in SemOpenAlex for { <https://semopenalex.org/work/W1495494087> ?p ?o ?g. }
- W1495494087 abstract "Objective To assess whether celecoxib, a selective cyclooxygenase‐2 ( COX ‐2) inhibitor with anti‐cancer properties, has an inhibitory effect on tumour establishment and progression of prostate cancer ( PCa ) bone metastases. Materials and Methods PC ‐3 stable luciferase‐expressing cells were injected into male nude mice by intracardiac (i.c.) and intratibial (i.t.) injections, and the effect of celecoxib on bone metastases was then recorded using bioluminescence image analysis. In cases of chemoprevention, mice received 3 mg/kg celecoxib from 1 week before cell implantation until the end of the study, and to test the therapeutic effect, mice received celecoxib 1 week after cell implantation until the end of the study. Tumour tissue samples were histologically examined and COX ‐2 expression was quantified at the protein level. Results Celecoxib significantly decreased cell viability and the proliferation of human PCa cells in vitro in a dose‐dependent manner. Bone metastases were detected after i.c. injection in nude mice. Celecoxib (15 ppm) administered before i.c. injection did not inhibit the cellular metastatic potential, as the numbers of bone metastases were similar in both groups. However, celecoxib did decrease metastatic progression in the osseous environment when cells were injected directly into the tibia ( P < 0.05). A t the protein level, COX ‐2 expression was significantly decreased in the celecoxib treatment group ( P < 0.01). Conclusion In a preclinical mice model, celecoxib administered orally at the standard human dose inhibits the progression of established PCa bone metastases." @default.
- W1495494087 created "2016-06-24" @default.
- W1495494087 creator A5009118055 @default.
- W1495494087 creator A5009695720 @default.
- W1495494087 creator A5012466556 @default.
- W1495494087 creator A5024002938 @default.
- W1495494087 creator A5045282403 @default.
- W1495494087 creator A5045537084 @default.
- W1495494087 creator A5047957100 @default.
- W1495494087 creator A5066444430 @default.
- W1495494087 creator A5068868892 @default.
- W1495494087 creator A5078613623 @default.
- W1495494087 creator A5079554721 @default.
- W1495494087 creator A5079903302 @default.
- W1495494087 date "2014-02-14" @default.
- W1495494087 modified "2023-10-06" @default.
- W1495494087 title "Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice" @default.
- W1495494087 cites W1420630981 @default.
- W1495494087 cites W1520425169 @default.
- W1495494087 cites W1522455546 @default.
- W1495494087 cites W1726054188 @default.
- W1495494087 cites W17682570 @default.
- W1495494087 cites W1837402230 @default.
- W1495494087 cites W1896893321 @default.
- W1495494087 cites W1971114732 @default.
- W1495494087 cites W1974450761 @default.
- W1495494087 cites W1982820124 @default.
- W1495494087 cites W1983104516 @default.
- W1495494087 cites W1986462334 @default.
- W1495494087 cites W1986471913 @default.
- W1495494087 cites W1993228606 @default.
- W1495494087 cites W1998232267 @default.
- W1495494087 cites W1998394615 @default.
- W1495494087 cites W1999429403 @default.
- W1495494087 cites W2000807708 @default.
- W1495494087 cites W2007845148 @default.
- W1495494087 cites W2010973568 @default.
- W1495494087 cites W2011185278 @default.
- W1495494087 cites W2016601849 @default.
- W1495494087 cites W2016759682 @default.
- W1495494087 cites W2024087814 @default.
- W1495494087 cites W2033425868 @default.
- W1495494087 cites W2034591836 @default.
- W1495494087 cites W2037438916 @default.
- W1495494087 cites W2040122586 @default.
- W1495494087 cites W2041676299 @default.
- W1495494087 cites W2044707121 @default.
- W1495494087 cites W2045995359 @default.
- W1495494087 cites W2050658186 @default.
- W1495494087 cites W2050888137 @default.
- W1495494087 cites W2052015579 @default.
- W1495494087 cites W2052720577 @default.
- W1495494087 cites W2053071688 @default.
- W1495494087 cites W2053315571 @default.
- W1495494087 cites W2054351138 @default.
- W1495494087 cites W2058118671 @default.
- W1495494087 cites W2059461233 @default.
- W1495494087 cites W2059871392 @default.
- W1495494087 cites W2060089292 @default.
- W1495494087 cites W2062858645 @default.
- W1495494087 cites W2070110479 @default.
- W1495494087 cites W2072308223 @default.
- W1495494087 cites W2072336398 @default.
- W1495494087 cites W2075477425 @default.
- W1495494087 cites W2077001806 @default.
- W1495494087 cites W2077950333 @default.
- W1495494087 cites W2078533938 @default.
- W1495494087 cites W2079338628 @default.
- W1495494087 cites W2080527581 @default.
- W1495494087 cites W2082833890 @default.
- W1495494087 cites W2087281763 @default.
- W1495494087 cites W2090636734 @default.
- W1495494087 cites W2092551711 @default.
- W1495494087 cites W2095170176 @default.
- W1495494087 cites W2098344528 @default.
- W1495494087 cites W2099540110 @default.
- W1495494087 cites W2102352213 @default.
- W1495494087 cites W2102405465 @default.
- W1495494087 cites W2102969047 @default.
- W1495494087 cites W2104364638 @default.
- W1495494087 cites W2107641357 @default.
- W1495494087 cites W2110430942 @default.
- W1495494087 cites W2112916072 @default.
- W1495494087 cites W2113701976 @default.
- W1495494087 cites W2123274778 @default.
- W1495494087 cites W2127560071 @default.
- W1495494087 cites W2129268315 @default.
- W1495494087 cites W2130517249 @default.
- W1495494087 cites W2132278017 @default.
- W1495494087 cites W2132441555 @default.
- W1495494087 cites W2132892424 @default.
- W1495494087 cites W2133125477 @default.
- W1495494087 cites W2139295697 @default.
- W1495494087 cites W2142016013 @default.
- W1495494087 cites W2142375064 @default.
- W1495494087 cites W2143157862 @default.
- W1495494087 cites W2146950484 @default.
- W1495494087 cites W2149640439 @default.
- W1495494087 cites W2161483205 @default.
- W1495494087 cites W2161962336 @default.